# A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

> **NCT05217355** · PHASE2 · COMPLETED · sponsor: **Medytox Korea** · enrollment: 50 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** MBA-P01 (Botulinum toxin A)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05217355
- **Lead sponsor:** Medytox Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-28
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217355, "A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05217355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*